HC Wainwright reaffirmed their buy rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a research report released on Tuesday morning, Price Targets.com reports. HC Wainwright currently has a $9.00 price objective on the biopharmaceutical company’s stock.
A number of other research analysts have also recently commented on the company. Roth Capital restated a buy rating on shares of Catalyst Pharmaceuticals in a research note on Sunday, August 15th. Zacks Investment Research upgraded Catalyst Pharmaceuticals from a hold rating to a buy rating and set a $6.25 target price for the company in a research note on Thursday, August 12th. Finally, Piper Sandler raised their target price on Catalyst Pharmaceuticals from $5.50 to $6.50 and gave the company an overweight rating in a research note on Tuesday, August 10th. Four equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $7.95.
NASDAQ CPRX opened at $4.90 on Tuesday. Catalyst Pharmaceuticals has a fifty-two week low of $2.88 and a fifty-two week high of $6.24. The stock has a 50 day simple moving average of $5.56 and a two-hundred day simple moving average of $5.14. The stock has a market cap of $504.59 million, a P/E ratio of 7.00 and a beta of 1.34.
In related news, Director Philip H. Coelho sold 9,498 shares of the firm’s stock in a transaction that occurred on Wednesday, August 25th. The stock was sold at an average price of $5.56, for a total transaction of $52,808.88. Following the completion of the transaction, the director now owns 233,427 shares of the company’s stock, valued at approximately $1,297,854.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Steve Miller sold 80,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 25th. The shares were sold at an average price of $5.56, for a total value of $444,800.00. Following the transaction, the chief operating officer now directly owns 821,724 shares of the company’s stock, valued at approximately $4,568,785.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 326,276 shares of company stock valued at $1,827,885. 11.70% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the business. Teacher Retirement System of Texas bought a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter worth $51,000. Brookstone Capital Management bought a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth $91,000. E Fund Management Co. Ltd. purchased a new position in shares of Catalyst Pharmaceuticals in the 1st quarter worth $84,000. XTX Topco Ltd purchased a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter worth $110,000. Finally, Lazard Asset Management LLC purchased a new position in shares of Catalyst Pharmaceuticals in the 1st quarter worth $99,000. 73.27% of the stock is owned by institutional investors and hedge funds.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms.
Further Reading: How to invest in blue-chip stocks
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.